FDA approves tiratricol, a thyroid-hormone analogue, for the rare disorder MCT8 deficiency
Emcitate cleared the FDA on 28 September as a new molecular entity. In an open-label trial of 45 patients, the drug lowered the high serum T3 that drives MCT8 deficiency by about two-thirds.
| Group | Value (nmol/L) |
|---|---|
| Baseline | 4.58 |
| On treatment | 1.66 |
The Food and Drug Administration has approved tiratricol for MCT8 deficiency, a rare inherited disorder that causes severe intellectual and motor disability. The approval was recorded in the agency's Drugs@FDA database on 28 September 2026 under new drug application 220963, held by Rare Thyroid Therapeutics International, and cleared as a Type 1 new molecular entity [s3]. The product, brand name Emcitate, is a 350 microgram oral tablet [s3]. Its labelling had not yet posted to the agency's public label file at the time of writing, so the account below rests on the drug's published trials.
MCT8 deficiency, also called Allan-Herndon-Dudley syndrome, is caused by loss of the thyroid-hormone transporter MCT8 [s1]. The defect produces a damaging split: tissues that depend on MCT8 to import thyroid hormone, including the brain, are starved of it, while the rest of the body is exposed to high circulating tri-iodothyronine (T3) [s1]. That chronic peripheral thyrotoxicosis drives weight loss, a fast heart rate and muscle wasting, and adds to the disorder's substantial morbidity and mortality [s1]. When the pivotal trial was run, no treatment that safely relieved the peripheral thyrotoxicosis was available [s1].
What the trials tested
Tiratricol, also written Triac, is an analogue of T3 that does not need MCT8 to enter cells [s1]. The registrational evidence comes from an investigator-initiated, multicentre, open-label, single-arm, phase 2 trial across eight European countries and one South African site [s1]. It enrolled 46 male paediatric and adult patients with MCT8 deficiency (median age 7.1 years, range 0.8 to 66.8), of whom 45 received the drug and had at least one follow-up thyroid measurement [s1]. Dosing started at 350 micrograms once daily and was escalated; patients needed a mean of 38.3 micrograms per kilogram of bodyweight to bring T3 into the target range [s1].
Because a single-arm trial has no concurrent control, a separate long-term study followed 67 patients across 33 sites for up to six years (median 2.2 years) to test whether the effect held [s2].
What they found
In the phase 2 trial, serum T3 fell from 4.97 nmol/L (standard deviation 1.55) at baseline to 1.82 nmol/L (0.69) at month 12 — a mean decrease of 3.15 nmol/L (95% confidence interval 2.68 to 3.62; P<0.0001) [s1]. The long-term cohort showed the same direction over years rather than months: mean T3 fell from 4.58 nmol/L (SD 1.11) to 1.66 nmol/L (0.69), a mean decrease of 2.92 nmol/L (95% CI 2.61 to 3.23) [s2].
The studies reported sustained improvement in the thyroid-hormone measures and the body-weight and heart-rate signs tied to the peripheral thyrotoxicosis [s1][s2]. The dose had to be individualised: patients needed widely differing amounts — a range of 6.4 to 84.3 micrograms per kilogram — to bring T3 into target, which is why the trial used a stepwise escalation rather than a fixed dose [s1].
Not every patient completed the phase 2 study. Of the 45 who started, five did not finish: two withdrew because of the travel burden or a pre-existing illness, one was lost to follow-up, one developed Graves' disease, and one died of sepsis [s1]. In a disorder this rare, those few cases are a reminder that the evidence base rests on small numbers of heavily affected patients followed at specialist centres, not on large populations.
How to read it
The clearest, best-documented effect is on the peripheral problem: tiratricol reliably lowers the high circulating T3 that damages the heart and muscle [s1][s2]. What it does for the central nervous system is the harder question. The disorder's most disabling features are neurological and are set early in development, and the trials measured chiefly the biochemical and systemic signs rather than long-term cognitive or motor outcomes [s1]. The evidence also carries the limits of its design — a single-arm study and a retrospective cohort, without a placebo comparison [s1][s2].
What to watch
The near-term questions are how the labelling defines the treated population and the age at which treatment begins, and whether real-world use reproduces the biochemical control the trials recorded [s2]. Whether earlier treatment changes the neurological course is the question that will take longest to answer.
Red flags: in a child or adult with MCT8 deficiency, a racing heartbeat, rapid weight loss or new breathing difficulty warrants prompt medical review [s1]. This article describes research and regulatory news and is not medical advice. Treatment of MCT8 deficiency is a decision for patients, families and their treating clinicians.
Sources
- Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency (phase 2 trial) — The Lancet Diabetes & Endocrinology, 31 July 2019
- Long-Term Efficacy of T3 Analogue Triac in Children and Adults With MCT8 Deficiency — The Journal of Clinical Endocrinology & Metabolism, 1 February 2022
- Drugs@FDA: Emcitate (tiratricol), NDA 220963 — new molecular entity approval record — U.S. Food and Drug Administration, approved 28 September 2026
Sources
- Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial — The Lancet Diabetes & Endocrinology , July 31, 2019
- Long-Term Efficacy of T3 Analogue Triac in Children and Adults With MCT8 Deficiency — The Journal of Clinical Endocrinology & Metabolism , February 1, 2022
- Drugs@FDA: Emcitate (tiratricol), NDA 220963 — new molecular entity approval record — U.S. Food and Drug Administration (openFDA drug/drugsfda API) , September 28, 2026
Givinostat slowed, but did not stop, motor decline in Duchenne muscular dystrophy
The oral histone deacetylase inhibitor cleared the FDA in March 2024. In the phase 3 EPIDYS trial, boys on givinostat still lost function over 72 weeks — just less of it than those on placebo.
FDA approves apitegromab, a myostatin inhibitor, for spinal muscular atrophy
The Scholar Rock antibody cleared the FDA on 11 September. In the phase 3 SAPPHIRE trial, apitegromab plus standard therapy beat placebo by 1.8 points on a motor-function scale at 12 months.
Sepiapterin, a new oral drug for phenylketonuria, cut blood phenylalanine by 63%
The FDA approved PTC Therapeutics' sepiapterin in July 2025. In the phase 3 APHENITY trial, responders saw a 63% fall in blood phenylalanine over six weeks against roughly no change on placebo.
FDA approves garetosmab for fibrodysplasia ossificans progressiva
Regeneron's activin A antibody, brand name Pasatru, cleared the FDA on 19 August. In the pivotal 63-patient trial, new abnormal-bone lesions fell by 90% or more against placebo over 56 weeks.